Celebrating its first anniversary, the American College of Radiology Image Metrix is reflecting on its past full year of operation, during which it has initiated projects for more than 12 drug and device companies.
 
The for-profit division of the American College of Radiology stated that it is pleased with the success of its business model. Stephen King, ACR Image Metrix chief operating officer, said, “There is a significantly higher level of awareness for the value imaging expertise can add to clinical trials, as well as a growing understanding of the role ACR Image Metrix can play in expediting clinical trials.”

Specifically, the Image Metrix works with pharmaceutical, biotech and medical device companies to integrate the appropriate imaging modalities and therefore increase the efficiency of drug development programs. Recent trials have focused on the capacity of molecular and functional imaging to serve as biomarkers of the effectiveness of anticancer treatments.

Morales said that Image Metrix will concentrate on CROs, pharmaceutical, biotech, and medical device companies to provide services in Phase I-III clinical trials.
 
ACR Image Metrix officials say the group is ahead in terms of its growth strategy, and it looks forward to accelerated growth in the next year.